Boehringer Ingelheim Vetmedica Inc. Enters Into an Agreement to Sell U.S. Feline, Canine and Rabies Vaccines Portfolio to Elanco Animal Health

ST. JOSEPH, Mo., Oct. 5, 2016 /PRNewswire/ -- Boehringer Ingelheim Vetmedica Inc. (BIVI) today announced an agreement with Elanco U.S., Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), to sell a portfolio of U.S. canine, feline and rabies vaccines, as well as a fully integrated manufacturing and R&D site, to Elanco. The sale price of $885 million includes the estimated cost of acquired inventory. The deal is conditioned on antitrust approval and closing of the Boehringer Ingelheim (BI) asset swap transaction with Sanofi that was signed in June 2016.

"This agreement is an important step toward a successful acquisition of Merial," said Dr. Albrecht Kissel, president and CEO of Boehringer Ingelheim Vetmedica Inc. "This was a highly complex decision from a business and from an emotional perspective. It was certainly not taken lightly particularly in view of the history and significant positive developments of this business over the past years."

"We are confident that, under Elanco's leadership, customers will continue to have access to these innovative vaccines and the portfolio will have strong support," Kissel added.

The current BIVI vaccine portfolio has experienced consistent revenue growth over the past three years. Just this year, the company launched two new vaccines, ULTRA^™ Hybrid^™ FVRCP and ULTRA™ Duramune^® Lyme, both available in the innovative 0.5mL dose developed by BIVI.

The sale to Elanco is anticipated to close by early 2017 subject to approval by the Federal Trade Commission, and other contingencies.

Products included within the proposed Elanco acquisition:

Canine:
Duramune^®

• Duramune^® Max 5/4L
• Duramune^® Max 5
• Duramune^® Max 5-Cvk/4L
• Duramune^® Max 5-Cvk
• Duramune^® Max Pv
• Duramune^® CV-K
• Duramune^® Max PC
• Duramune^® Adult 3
• LeptoVax^® 4
• LeptoVax^® 4/C

Bronchi-Shield^®

• Bronchi-Shield^® ORAL
• Bronchi-Shield^® III

Duramune Lyme^®

• Duramune Lyme^® 
• Duramune Lyme^® +LeptoVax^® 4
• Duramune Lyme^® +Leptovax^® 4/C
• Duramune Lyme^® +Max 5/4L
• Duramune Lyme^® +Max5-CvK/4L
• Duramune Lyme^® +Max5-CvK

ULTRA^™ Duramune^®

• ULTRA^™ Duramune^® DAP+4L
• ULTRA^™ Duramune^® DAP
• ULTRA^™ Duramune^® 4L
• ULTRA^™ Duramune^® DAP+C4L
• ULTRA^™ Duramune^® DAP+C
• ULTRA^™ Duramune^® Lyme

Feline:
Fel-O-Vax^® 

• Fel-O-Vax Lv-K^® III + CaliciVax^®
• Fel-O-Vax^® Lv-K^®
• Fel-O-Vax^® Lv-K/FIV
• Fel-O-Vax^® IV+CaliciVax^®
• Fel-O-Vax^® PCT+CaliciVax^®
• Fel-O-Vax^® Lv-K IV+CaliciVax^®
• Fel-O-Vax^® FIV
• CaliciVax^®

ULTRA^™ Fel-O-Vax^® 

• ULTRA^™ Fel-O-Vax^® FVRCP+FeLV
• ULTRA^™ Fel-O-Vax^® FVRCP
• ULTRA^™ Fel-O-Vax^® FeLV
• ULTRA^™ Fel-O-Vax^® Dual FCV
• ULTRA^™ Hybrid^™ FVRCP

Fel-O-Guard^®

• Fel-O-Guard^® Plus 3
• Fel-O-Guard^® Plus 3+Lv-K
• Fel-O-Guard^® Plus 4
• Fel-O-Guard^® Plus 4 +Lv-K

Rabies
Rabvac^®

• Rabvac^® 3
• Rabvac^® 1

About Boehringer Ingelheim Vetmedica, Inc. (BIVI)

Boehringer Ingelheim Vetmedica, Inc. (BIVI), is the U.S. animal health division of Boehringer Ingelheim GmbH. BIVI develops, manufactures and markets novel and innovative solutions for the prevention and treatment of disease in the cattle, equine, pet and swine markets. BIVI is the fifth largest animal health company in the U.S. Our U.S. headquarters is located within the KC Animal Health Corridor in St. Joseph, Mo. We have 2,000 employees unleashing their collective passion to keep animals healthy every day.

With more than 3,800 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about 1.4 billion euros in 2015. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 11 percent of net sales of the Animal Health business in R&D.

Boehringer Ingelheim is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally through 145 affiliates and a total of some 47,500 employees. Founded in 1885, the focus of the family-owned company is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the "Making More Health" initiative while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.

For more information, please visit bi-vetmedica.com.

SOURCE Boehringer Ingelheim Vetmedica Inc.

Related Links

http://www.bi-vetmedica.com